Jump to content

Uramustine

From Wikipedia, the free encyclopedia

This is an old revision of this page, as edited by DePiep (talk | contribs) at 22:36, 2 April 2016 (Remove redundant parameters InChI, InChIKey (StdInChI, StdInChIKey are used). See Talk (via AWB script)). The present address (URL) is a permanent link to this revision, which may differ significantly from the current revision.

Uramustine
Clinical data
ATC code
  • none
Pharmacokinetic data
Protein binding5%
ExcretionRenal
Identifiers
  • 5-[bis(2-chloroethyl)amino]-1H-pyrimidine-2,4-dione
CAS Number
PubChem CID
IUPHAR/BPS
DrugBank
ChemSpider
UNII
KEGG
ChEMBL
CompTox Dashboard (EPA)
ECHA InfoCard100.000.574 Edit this at Wikidata
Chemical and physical data
FormulaC8H11Cl2N3O2
Molar mass252.097 g/mol g·mol−1
3D model (JSmol)
  • O=C1C(\N(CCCl)CCCl)=C/NC(=O)N1
  • InChI=1S/C8H11Cl2N3O2/c9-1-3-13(4-2-10)6-5-11-8(15)12-7(6)14/h5H,1-4H2,(H2,11,12,14,15) ☒N
  • Key:IDPUKCWIGUEADI-UHFFFAOYSA-N ☒N
 ☒NcheckY (what is this?)  (verify)

Uramustine (INN) or uracil mustard is a chemotherapy drug which belongs to the class of alkylating agents. It is used in lymphatic malignancies such as non-Hodgkin's lymphoma. It works by damaging DNA, primarily in cancer cells that preferentially take up the uracil due to their need to make nucleic acids during their rapid cycles of cell division. The DNA damage leads to apoptosis of the affected cells. Bone marrow suppression and nausea are the main side effects.

Chemically it is a derivative of nitrogen mustard and uracil.